Ambrosia Bio Ltd.

Ambrosia Bio is a biotechnology company that has developed a proprietary enzyme-based platform designed to convert common sugars and feedstocks, such as sucrose, into rare, low-calorie sugars like allulose. The company’s approach involves a plug-and-play bioprocess that integrates into existing sugar refinery and starch processing infrastructure, allowing manufacturers to produce these high-value ingredients without significant operational modifications. By utilizing synthetic enzymes that demonstrate high stability and catalytic activity, the platform offers a cost-effective alternative to traditional production methods, aiming to overcome the scale and affordability barriers associated with mass-market allulose adoption.

This technology provides food and beverage manufacturers with a solution to reduce sugar content in consumer products while maintaining the taste profile, texture, and sensory experience of traditional sugar. By enabling producers to diversify their portfolios between conventional and health-focused ingredients, Ambrosia Bio supports the industry's shift toward healthier food options, particularly for diabetic patients and weight-conscious consumers. The company has engaged in strategic partnerships, including collaborations with Ginkgo Bioworks to further optimize its enzyme expression strains and production processes, as it works with international food and beverage producers to implement its sugar reduction solutions.